MYNZ
Mainz Biomed B.V.
NASDAQ · Healthcare · Medical - Diagnostics & Research · DE
$3.59
+0.84%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4M | 537.1K | 894.0K | 895.5K | 529.9K |
| Cost of Revenue | 1.1M | 147.3K | 319.1K | 385.8K | 347.7K |
| Gross Profit | 304.8K | 389.8K | 574.9K | 509.7K | 182.2K |
| Operating Expenses | |||||
| R&D Expense | 12.5M | 4.9M | 5.8M | 9.6M | 3.7M |
| SG&A Expense | 26.4M | 8.9M | 12.8M | 17.2M | 22.8M |
| General & Admin Expense | 14.5M | 5.1M | 8.1M | 13.4M | 17.8M |
| Selling & Marketing Expense | 8.3M | 3.8M | 4.7M | 3.8M | 5.0M |
| Other Expenses | 2.1M | 2.5M | 656.3K | 342.4K | (114.0K) |
| Total Operating Expenses | 41.0M | 16.4M | 19.3M | 27.2M | 26.4M |
| Cost and Expenses | 42.0M | 16.5M | 19.6M | 27.5M | 27.0M |
| Operating Income (EBIT) | (39.0M) | (16.1M) | (18.7M) | (26.6M) | (26.4M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 2.6M | (373.5K) | 1.1M | 809.6K | 289.3K |
| Net Interest Income | (1.9M) | — | (1.1M) | (809.6K) | (289.3K) |
| Other Non-Op Income/Expense | (2.5M) | (71.6K) | (3.0M) | 349.0K | 56.7K |
| Non-Operating Income (excl Interest) | 1.9M | — | 1.9M | (599.0K) | (346.0K) |
| EBT (Pre-Tax Income) | (35.2M) | (16.2M) | (21.7M) | (26.3M) | (26.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (35.2M) | (16.2M) | (21.7M) | (26.3M) | (26.5M) |
| Earnings from Cont. Ops | (35.2M) | (16.2M) | (21.7M) | (26.3M) | (26.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (35.2M) | (16.2M) | (21.7M) | (26.3M) | (26.4M) |
| Per Share | |||||
| Basic EPS | ($41.82) | ($2.70) | ($22.36) | ($1.62) | ($1.87) |
| Diluted EPS | ($41.82) | ($2.70) | ($22.36) | ($1.62) | ($1.87) |
| Revenue Per Share | $0.44 | $0.09 | $0.92 | $0.06 | $0.04 |
| Shares | |||||
| Basic Shares Outstanding | 3.1M | 6.0M | 968234 | 16.2M | 14.2M |
| Diluted Shares Outstanding | 3.1M | 6.0M | 968234 | 16.2M | 14.2M |
| Profitability Metrics | |||||
| EBITDA | (39.9M) | (16.1M) | (19.6M) | (25.0M) | (25.7M) |
| D&A | 1.8M | — | 1.0M | 1.0M | 459.4K |
| EBIT | (41.7M) | — | (20.6M) | (26.0M) | (26.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025